IL222120A - Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs - Google Patents

Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs Download PDF

Info

Publication number
IL222120A
IL222120A IL222120A IL22212012A IL222120A IL 222120 A IL222120 A IL 222120A IL 222120 A IL222120 A IL 222120A IL 22212012 A IL22212012 A IL 22212012A IL 222120 A IL222120 A IL 222120A
Authority
IL
Israel
Prior art keywords
preparation
indol
medicaments
pharmaceutical compositions
treating cancer
Prior art date
Application number
IL222120A
Other languages
English (en)
Hebrew (he)
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IL222120A publication Critical patent/IL222120A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL222120A 2010-03-25 2012-09-24 Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs IL222120A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31747610P 2010-03-25 2010-03-25
US35286310P 2010-06-09 2010-06-09
US38148010P 2010-09-10 2010-09-10
US38815110P 2010-09-30 2010-09-30
US41906810P 2010-12-02 2010-12-02
PCT/US2011/029511 WO2011119663A1 (en) 2010-03-25 2011-03-23 Chemical compounds

Publications (1)

Publication Number Publication Date
IL222120A true IL222120A (en) 2015-09-24

Family

ID=46160738

Family Applications (1)

Application Number Title Priority Date Filing Date
IL222120A IL222120A (en) 2010-03-25 2012-09-24 Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs

Country Status (15)

Country Link
US (1) US20120077828A1 (enExample)
EP (1) EP2549868B1 (enExample)
JP (1) JP5876031B2 (enExample)
KR (1) KR101676077B1 (enExample)
CN (1) CN102917588B (enExample)
AR (1) AR080792A1 (enExample)
AU (1) AU2011232516B2 (enExample)
EA (1) EA022325B1 (enExample)
ES (1) ES2530955T3 (enExample)
IL (1) IL222120A (enExample)
MX (1) MX2012011045A (enExample)
SG (1) SG183954A1 (enExample)
TW (1) TW201202241A (enExample)
UY (1) UY33288A (enExample)
WO (1) WO2011119663A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012024380A2 (pt) * 2010-03-25 2015-09-15 Glaxosmithkline Llc compostos químicos
WO2012158123A1 (en) * 2011-05-13 2012-11-22 Agency For Science, Technology And Research Compounds and methods for treating insulin resistance syndrome
LT2734522T (lt) 2011-07-19 2019-02-11 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk-inhibitoriai
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US9550750B2 (en) 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
TWI498325B (zh) * 2013-01-18 2015-09-01 Hoffmann La Roche ３－取代吡唑及其用途
AU2014247215B2 (en) * 2013-04-04 2018-05-10 Janssen Pharmaceutica Nv Novel N-(2,3-dihydro-1H-pyrrolo[2,3-b]jpyridin-5-yl)-4- quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4- quinazolinamine derivatives as perk inhibitors
TWI482757B (zh) * 2013-10-07 2015-05-01 Luminescence Technology Corp Ｖｅｇｆ－２／３受體及蛋白質酪胺酸激酶抑制劑及其醫藥用途
WO2015056180A1 (en) * 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
EP3076974A1 (en) 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015136463A1 (en) * 2014-03-11 2015-09-17 Glaxosmithkline Intellectual Property (No.2) Limited Chemical compounds acting as perk inhibitors
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US9949971B2 (en) 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
US20170231986A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor
PE20190710A1 (es) * 2014-10-24 2019-05-17 Bristol Myers Squibb Co Compuestos de indol carboxamida utiles como inhibidores de cinasas
PL3218378T3 (pl) 2014-11-14 2020-10-19 Nerviano Medical Sciences S.R.L. Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
WO2016126026A2 (ko) * 2015-02-04 2016-08-11 서울대학교병원 당뇨병 치료 조성물 및 이의 용도
LT3317281T (lt) 2015-07-02 2020-07-27 Acerta Pharma B.V. (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamido kompozicijų kietosios formos
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
ES2921855T3 (es) * 2016-04-07 2022-09-01 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
ES2886587T3 (es) * 2016-04-15 2021-12-20 Cancer Research Tech Ltd Compuestos heterocíclicos como inhibidores de la quinasa RET
US11026945B2 (en) * 2016-04-29 2021-06-08 The Trustees Of The University Of Pennsylvania Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
WO2017216792A1 (en) 2016-06-13 2017-12-21 Ramot At Tel-Aviv University Ltd. Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
EP3472165B1 (en) 2016-06-21 2023-09-06 Nerviano Medical Sciences S.r.l. N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
WO2018015879A1 (en) * 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
WO2018055578A1 (en) * 2016-09-22 2018-03-29 The University Of Hong Kong Preventive and therapeutic approach for aberrant cell differentiation and isr-associated diseases
US20190388426A1 (en) 2017-01-30 2019-12-26 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
CN106974910B (zh) * 2017-03-02 2019-11-12 深圳大学 含索拉非尼和gsk2656157的药物组合物及用途
CN106963769B (zh) * 2017-03-03 2019-10-25 深圳大学 含pi3k抑制剂和perk抑制剂的药物组合物及其应用
JP6637217B2 (ja) 2017-03-06 2020-01-29 株式会社坪田ラボ 近視予防又は抑制剤、マウス近視誘導モデルの作製方法、及び、近視予防又は抑制医薬スクリーニング方法
KR102007135B1 (ko) * 2017-03-20 2019-08-02 포르마 세라퓨틱스 인크. 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
WO2019021208A1 (en) * 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
AU2018358160B2 (en) 2017-11-02 2023-03-16 Abbvie Inc. Modulators of the integrated stress pathway
CN108003163B (zh) * 2017-11-30 2020-11-24 武汉九州钰民医药科技有限公司 用作激酶抑制剂的吡唑并嘧啶类化合物及其应用
CN111100130B (zh) * 2018-10-29 2022-07-15 四川大学 4-氨基吡咯并嘧啶衍生物及其制备方法和用途
CN111213632B (zh) * 2019-11-19 2022-03-01 长春中医药大学 动物药环氧树脂标本制作方法
WO2021252488A1 (en) 2020-06-08 2021-12-16 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212326A1 (en) 2021-03-29 2022-10-06 Halia Therapeutics, Inc. Nek7 inhibitors
EP4320127A1 (en) 2021-04-05 2024-02-14 Halia Therapeutics, Inc. Nek7 inhibitors
WO2023034236A1 (en) * 2021-08-31 2023-03-09 Wisconsin Alumni Research Foundation Deuterated inhibitors of rip kinases
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566158A1 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
JP2009514899A (ja) * 2005-11-04 2009-04-09 スミスクライン ビーチャム コーポレーション チエノピリジンＢ−Ｒａｆキナーゼ阻害剤
AU2007272330A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
WO2009151621A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
JP5746032B2 (ja) * 2008-09-19 2015-07-08 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ３，４−ジヒドロ−２Ｈ−ピロロ［１，２−ａ］ピラジン−１−オン誘導体

Also Published As

Publication number Publication date
CN102917588A (zh) 2013-02-06
KR20130018272A (ko) 2013-02-20
EA022325B1 (ru) 2015-12-30
CN102917588B (zh) 2014-10-08
JP2013534902A (ja) 2013-09-09
EA201290952A1 (ru) 2013-04-30
AU2011232516B2 (en) 2014-08-07
TW201202241A (en) 2012-01-16
UY33288A (es) 2011-10-31
KR101676077B1 (ko) 2016-11-14
EP2549868A1 (en) 2013-01-30
AU2011232516A1 (en) 2012-10-04
EP2549868B1 (en) 2015-01-07
MX2012011045A (es) 2012-11-16
WO2011119663A8 (en) 2012-10-26
AR080792A1 (es) 2012-05-09
ES2530955T3 (es) 2015-03-09
US20120077828A1 (en) 2012-03-29
WO2011119663A1 (en) 2011-09-29
JP5876031B2 (ja) 2016-03-02
EP2549868A4 (en) 2013-08-07
SG183954A1 (en) 2012-10-30
AU2011232516A8 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
IL222120A (en) Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
IL268756B (en) Piperazine-2,5-dione derivatives, pharmaceutical preparations containing them and their use for the preparation of medicines
IL253000B (en) Tricyclic pyrazolyl compounds, their use for the preparation of drugs for the treatment of cancer and pharmaceutical preparations containing them
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
IL230874A (en) History of dihydroquinoline-2-on-egg scallops, their preparation process, pharmaceutical preparations containing them and their use in the preparation of drugs
IL231168B (en) Benzenesulfonamide history of quinoxaline, their pharmaceutical preparations and their use for the preparation of a drug for the treatment of cancer
IL222600A (en) Derivatives of 3- (pyrazole-4-ram) -6-phenylamino-quinoxaline, their preparation, combinations and preparations containing them and their use in the manufacture and treatment of cancer prevention drugs
IL215065A (en) Proline derivatives, their preparation process, their pharmaceutical compositions and their uses in drug preparation
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
AP3438A (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
IL217490A (en) History of pyridine-4-il, pharmaceutical preparations containing them and their use in the preparation of medicines
SI2807159T1 (sl) Novi derivati indolizina, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo, za zdravljenje raka
IL203936A (en) HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation
IL219309A (en) History of glycoside, including pharmaceutical preparations and their use in the preparation of diabetes medications
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
IL205665A (en) The history of terroiril, the process of preparing them, the drugs containing them and their use in the preparation of drugs
ZA201206062B (en) Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
IL207684A (en) Preserved indole history, a method for making these histories, drugs containing these histories, and their use in making drugs
IL226205B (en) Fusion proteins, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of cancer
IL213983A (en) Derivatives of pyridazinone that are converted into heteroaryl, their process, their pharmaceutical preparations and their use in the preparation of drugs
IL226095A0 (en) The history of pyridine and its use in pharmaceutical preparations for the treatment of cancer
IL223872A (en) Pyrazoloquinoline derivatives and intermediates, process for preparation, use and pharmaceutical preparations and preparations containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees